Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-GEND-pIII recurrent glioblastoma study
jRCTs031180083Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing Bevacizumab alone with Dose-dense temozolomide followed by bevacizumab (2 arms). Primary endpoint: Overall survival. Started Jul 2016; status: completed.
02
Drugs
bevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCTs031180083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180083.